Clinical Trial

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 23, 2025 (before its estimated July 16, 2026 completion). Its status may not reflect the trial's current state.
Summary
In decades, the outcome of patients with peripherial T-cell lymphomas is dismal, especially in relapsed or refractory population. After failure to the frontline treatment, patients have limited treatment options and elderly population usually have no chance to undergo transplantation due to age or comorbidity, etc. Golidocitinib and chidamide were approved in treating r/r PTCL in China, while azacytidine has been demonstrated its anti-tumor activity in PTCL as well. This study aims to explore the efficacy and safety of golidocitinib combined with azacytidine and chidamide in the patients with peripheral T-cell lymphoma who are eligible for intensive chemotherapy or transplantation.
Trial Details
NCT Number NCT07081607
Lead Sponsor Ruijin Hospital
Conditions Peripheral T-Cell Lymphoma, Not Classified
Enrollment 30 participants
Start Date 2025-07-15
Primary Completion 2026-07-16 (estimated)
Study Completion 2028-07-16 (estimated)
Updated on ClinicalTrials.gov 2025-07-23